Figure 1.
Figure 1. Patient 1 timeline, clinical progression, and intraocular disease burden. (A) Timeline of case 1, including the immunophenotype of the various tumor sites and the intraocular involvement. This timeline highlights the evolution of the immunophenotypic switch, the diagnosis of intraocular involvement, and the subsequent treatments. (B) The new cutaneous tumors, which erupted in 2008, were the first evidence of immunophenotypic switch from CD4+ to mixed CD4+/CD8+. (C) Anterior segment photograph demonstrating anterior chamber cellular reaction with keratic precipitates composed of tumor cells on the endothelial surface of the cornea. These intraocular cells were CD4−/CD8+.

Patient 1 timeline, clinical progression, and intraocular disease burden. (A) Timeline of case 1, including the immunophenotype of the various tumor sites and the intraocular involvement. This timeline highlights the evolution of the immunophenotypic switch, the diagnosis of intraocular involvement, and the subsequent treatments. (B) The new cutaneous tumors, which erupted in 2008, were the first evidence of immunophenotypic switch from CD4+ to mixed CD4+/CD8+. (C) Anterior segment photograph demonstrating anterior chamber cellular reaction with keratic precipitates composed of tumor cells on the endothelial surface of the cornea. These intraocular cells were CD4/CD8+.

Close Modal

or Create an Account

Close Modal
Close Modal